February 7, 2018 –
4.1 million Investment results in upgrade to SKYEPHARMA Development & Manufacturing site in Lyon. Acquisition of a new Marchesini bottling line will improve capacity and capabilies from March 2018.
David LESCUYER – EVP Vectura Group of Companies – President of SKYEPHARMA PRODUCTION SAS:
“With all the investments made on our site, we are now able to offer a full range of CDMO services, from early stage development to manufacturing and packaging, including serialization and aggregation. Skyepharma is now a fully integrated One-Stop-Shop for complex oral solid dosage forms. We have the capabilities, we have the capacity and we have a great team that makes a difference to our customers”
The investment of a brand new bottling line from Marchesini follows the plan started April 2016, allowing Skyepharma to position itself as a credible actor in the CDMO market place. This new packaging line including all recent features such as serialization, aggregation, will be up and running next month, in March 2018. This line is able to produce over 15 million bottles per year.
In addition to this bottling line, a brand new blistering line has also been ordered to Marchesini, with a capacity of over 50 million blister packs, and will be installed and qualified by first quarter 2019.
Skyepharma has now state-of-the-art capabilities in early stage development, with the Styl’One Evolution installed end of 2016, and is already working with several new clients on early stage developments as well as strategic technical transfers.